A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer

NCT06409390 Phase 2 RECRUITING

The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.

Details

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 2
Status	RECRUITING
Enrolment	15
Start date	2024-08-14
Completion	2027-04

Conditions

• Metastatic Breast Cancer

Interventions

• Taxotere
• Cytoxan
• Trastuzumab deruxtecan
• Sacituzumab govitecan
• Xeloda
• Fulvestrant
• Ribociclib
• Abemaciclib

Primary outcomes

• Feasibility of Sequential Therapy — Up to 18 months
  The proportion of patients able to complete the sequence of therapies by the conclusion of the trial.

Countries

United States